Hiroki Inada

11PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersDisease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTissue engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 06, 2026
Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab.

|May 06, 2026
Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

|Mar 18, 2026
Impact of Etiological Shifts and the Rising Burden of Non-B Non-C Hepatocellular Carcinoma on Surveillance and Prognosis: Insights From a 20-Year Retrospective Observational Study.

Yoko Yoshimaru, Katsuya Nagaoka, Hiroko Setoyama

|May 03, 2025
Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis.

Hiroki Inada, Katsuya Nagaoka, Kenyu Hashimoto

|May 03, 2025
Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Takanori Suzuki, Kentaro Matsuura, Satoshi Sobue

|Nov 29, 2023
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.

Yoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka

Pageof 2

Frequent Collaborators

10 joint publications

Yasuhito Tanaka

5 joint publications

Takayuki Tokunaga

4 joint publications

Satoshi Narahara

4 joint publications

Katsuya Nagaoka